Adenosine as adjunctive therapy in acute coronary syndrome: a meta-analysis of randomized controlled trials
Authors' conclusion
Adenosine infusion, as adjunctive therapy in ACS, was associated with an increased risk of advanced atrioventricular blocks and increased rates of adenosine-triggered ventricular arrhythmias in patients with long ischaemic time, without providing any clinical benefit compared to placebo.
Study context
- Population
- Patients with acute coronary syndrome (ACS) undergoing myocardial revascularization
- Participants
- 5,843 patients26 randomized controlled trials (RCTs)
- Comparison
- Intracoronary or intravenous adenosine vs placebo
- Outcome
- Efficacy endpoints: MACE, all-cause death, non-fatal MI and HF
Methodological detailsPubMed and Scopus searched up to 5th June 2022
- PubMed and Scopus searched up to 5th June 2022
Pooled result
As reported in the abstract
MACE, all-cause death, non-fatal MI, HF
- Adenosine not associated with any clinical benefit in major adverse cardiac events (MACE), all-cause death, non-fatal MI or HF
Further pooled results
Myocardial blush grade 0-1 and thrombolysis in myocardial infarction (TIMI) flow grade 0-2 (PCI subgroup)
- Adenosine associated with reduced myocardial blush grade 0-1 and TIMI flow grade 0-2 vs placebo
Left ventricular ejection fraction (LVEF) and infarct size
- No favourable effects of adenosine
Safety
- Adenosine associated with increased rate of advanced atrioventricular blocks and of VF/SVT in studies with total mean ischaemic time >3 h, vs placebo
Original publication
Adenosine as adjunctive therapy in acute coronary syndrome: a meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother. Published 10 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →